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the target vessel or TLR.
Results: There was no difference in patient baseline characteristics. Lesion length was
11.26.5mm in the DCB- and 12.28.2mm in the POBA-group (p¼n.s). Post PCI,
for the stented segment and the total segment minimal lumen diameter and diameter
stenosis were not different. Clinical follow-up after 12 months was 100%. Treatment
with DCB was superior to balloon angioplasty alone with an in-stent late loss of
0.430.61mm vs. 1.030.77mm (p< 0.001). Minimal lumen diameter was signiﬁ-
cantly larger and percent diameter stenosis signiﬁcantly lower with use of the DCB for
both the stented and total segment. Restenosis rate was reduced from 58.1% to 17.2%
(P< 0.001) and the clinical endpoint at 6 months was reduced from 50% to 16.7% (P<
0.001), respectively. After 12 months the effect of DCB persisted (clinical endpoint
52.6% vs. 16.7%; p< 0.001 and TLR 36.8% vs. 15.3%, p¼0.005), respectively. There
was one probable stent thrombosis in the POBA group. Clinical follow-up after 3
years will be completed in June 2014 and presented.
Conclusions: Paclitaxel coated balloon angioplasty was superior to balloon angio-
plasty alone for the treatment of instent-restenosis of drug-eluting stents. Longterm
effects of the DCB-therapy after 3 years will be presented.
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Background: Previous studies demonstrated that angioplasty with a paclitaxel-coated
balloon (PCB) was non-inferior to paclitaxel-eluting stent (PES) implantation when used
to treat drug-eluting stent in-stent restenosis (DES-ISR). There is a paucity of data
regarding the long-term safety and efﬁcacy of using PCB in treating DES-ISR.We sought
to present for the ﬁrst time the 2-year clinical outcomes from PEPCAD China ISR trial.
Methods: PEPCAD China ISR was a 220 patient randomized (1:1), single blind
prospective multicenter trial conducted in China. Patients with DES-ISR received
either PCB (SeQuent Please, B.Braun Melsungen AG, Germany) or PES (Taxus
Liberté, Boston Scientiﬁc, Natick, MA, USA) treatment. The primary endpoint was in-
segment late lumen loss (LLL) at 9 months. Secondary endpoints included 9-month %
diameter stenosis (DS), binary restenosis rate, and 1- and 2-year target lesion failure
(TLF) deﬁned as the composite of cardiac death, target vessel myocardial infarction or
ischemia-driven target lesion revascularization. In addition, deﬁnite/probable stent
thrombosis (ST) rates were documented.
Results: At 9 months, the in-segment LLL, %DS and binary restenosis were not
signiﬁcantly different between PCB and PES group (0.460.51mm vs.
0.550.61mm; 29.0  21.3 vs. 30.8  25.3; 18.6% vs. 23.8%; p>0.05 respectively).
No adverse ischemic events occurred between 1 to 2 years in PCB group except 1 non-
target vessel revascularization. However, the rate of all-cause death was statistically
lower in the PCB group (0% vs. 4.9%, p¼0.03) compared with PES group at 2 years.
Major results are shown in the table.Table. Clinical Outcomes through 2 Years
12 Months 24 Months
PCB,
n¼109
PES,
n¼106 p
PCB,
n¼107
PES,
n¼102 p
Death, % (n) 0 (0) 1.9 (2) 0.24 0 (0) 4.9 (5) 0.03
Cardiac Death, % (n) 0 (0) 0 (0) - 0 (0) 2.0 (2) 0.24
Myocardial Infarction, % (n) 3.7 (4) 6.6 (7) 0.33 3.7 (4) 6.9 (7) 0.31
Q Wave MI, % (n) 0 (0) 0.9 (1) 0.49 0 (0) 1.0 (1) 0.49
Target Vessel MI, % (n) 2.8 (3) 6.6 (7) 0.21 2.8 (3) 6.9 (7) 0.21
Ischemia-Driven TLR, % (n) 14.7 (16) 10.4 (11) 0.34 15.0 (16) 11.8 (12) 0.5
TLR, % (n) 15.6 (17) 12.3 (13) 0.48 15.9 (17) 13.7 (14) 0.66
TVR, % (n) 16.5 (18) 16.0 (17) 0.92 16.8 (18) 17.7 (18) 0.87
Any Revascularization, % (n) 22.0 (24) 17.9 (19) 0.45 23.4 (25) 20.6 (21) 0.63
TLF, % (n) 16.5 (18) 16.0 (17) 0.92 16.8 (18) 18.6 (19) 0.73
PoCE (composite of all
cause death, all MI, and any
revascularization), % (n)
23.9 (26) 23.6 (25) 0.96 25.2 (27) 30.4 (31) 0.41
Deﬁnite or Probable Stent
Thrombosis, % (n)
0.9 (1) 0.9 (1) 1.00 0.9 (1) 1.0 (1) 1.00Conclusions: The prolonged 2-year clinical follow-up showed that there was no
newly occurred death, MI, TVR, or ST in PCB group between 1 and 2 years, and
statistically, a lower all-cause mortality of PCB compared to PES for the treatment of
DES-ISR. (ClinicalTrials.gov identiﬁer: NCT 01622075)B78 JACC Vol 64/11/Suppl B j September 13–17,TCT-268
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Background: Stents are needed in up to 50 % of all peripheral interventions where
PTA with plain or drug-coated balloons alone will not reopen the vessel sufﬁciently.
Nevertheless, the restenosis rate of stents is still a major limitation of peripheral
arterial interventions. Drug-coated balloons potentially overcome the problem of in-
stent restenosis when used for postdilatation after primary nitinol stenting in the SFA
and PI segment.
Methods: The Freeway Stent Study is a prospective, randomized, international trial
started in 15 centers in Germany and Austria. 200 patients will be enrolled and ran-
domized equally to primary nitinol stenting followed by either DCB (Freeway) or
plain balloon postdilatation. Primary endpoint is clinically driven target lesion revas-
cularization (TLR) at 6 months, secondary endpoints include further clinical and safety
evaluations like shift in Rutherford classiﬁcation and ABI, LLL, patency rate andMAE.
Results: Over 170 patients have been enrolled to date, of which 130 have ﬁnished the
6 months and almost 100 the 12 months follow-up. The results highly favor the use of
Freeway DCB over plain balloon based on clinically driven TLR (only 3.2 % vs.
10.2 % at 6 months and 8.0 % vs. 17.4 % at 12 months). This is supported by a
statistically signiﬁcant better clinical outcome for PAD patients treated with DCB as
postdilatation device regarding primary patency rate, ABI and Rutherford classiﬁca-
tion at six months.
Conclusions: The use of DCB as postdilatation device is investigated in a new
approach to decrease the restenosis rate after nitinol stenting in the SFA and PI
segment. The latest interim results of the Freeway Stent Study show that DCB
might signiﬁcantly lower the in-stent restenosis rate in the treatment of PAD
patients.
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Background: Drug coated balloons (DCB) have provided a new option in the
treatment of peripheral artery disease, because they allow elution of an anti-
proliferative agent into the vessel wall. With the standard methods like the plain old
balloon angioplasty (POBA) the effort to restore the normal ﬂow often fails due to
restenosis. The FREERIDE study investigates the inhibition of restenosis by the
(Paclitaxel) DCB Freeway (Eurocor GmbH, Bonn, Germany) versus standard balloon
PTA, in the treatment of de-novo occluded, stenotic or reoccluded lesions in pe-
ripheral arteries (SFA and popliteal artery/PI segment).
Methods: Controlled multicenter trial conducted in 23 centers worldwide with 280
PAD patients randomized either to Freeway DCB or to POBA. The primary endpoint
is the rate of target lesion revascularization (TLR) at 6 months. Further, several sec-
ondary endpoints like late lumen loss and patency rate at 6 months, TLR at 12, 24
months follow up (FU), change in the Ankle-brachial index (ABI) and Rutherford
classiﬁcation at FU, and MAE are investigated.
Results: Until the date 84 patients have been enrolled, 62 completed the 6 months
FU, 8 have not been available for FU. The interim results show that there was
remarkably more bail out stenting after POBA compared with Freeway PTA (8.9%
vs. 25.6%; p¼0.04). After 6 months there were clear positive trends in the TLR
rate for the Freeway arm (5.4% vs. 20%; p¼0.07). MAE were signiﬁcant lower in
the Freeway arm compared to POBA (5.4% vs. 28%; p¼0.01) with 0% vs. 8%
death, 0 % both arms for study related amputation and thrombosis. Furthermore
there were promising clinical outcomes in Rutherford classiﬁcation after Freeway
vs. POBA.
Conclusions: The interim results indicate that the (Paclitaxel)-coated balloon Freeway
might provide an advantage for PTA in SFA lesions and PI segment. The drug coated
balloons could result in better outcomes overcoming the existing limitations in pe-
ripheral artery disease treatment.2014 j TCT Abstracts/Drug-Eluting Balloons and Local Drug Delivery
